NeoDynamics AB

The Challenge

The primary cause of death from cancer is the spread of metastases within the body from the original primary tumor. Early diagnosis and treatment is therefore essential to minimize the risk of cancer cells spreading or seeding early, in order to reduce mortality.

NeoDynamic’s Solution

NeoDynamics is developing two principal methods for safe gentle biopsy sampling and safe, early, minimally-invasive cancer treatment.

Fourier/AS – The company's projection-free inertia-stabilized versatile core needle biopsy device, is equipped with Anti-Seeding functionality that prevents tumor cells from spreading during the biopsy procedure. Core needle biopsies of different diameters and tissue lengths can be removed and numerous tissue blocks can be extracted through the same needle channel.

Preferential Radiofrequency Ablation (PRFA) – A new method for primary treatment of breast cancer with dedicated equipment activated by radiofrequency energy. The electrode is positioned centrally in the tumor by ultrasound guidance. Unique Fourier Power Assistance helps to position the electrode precisely even in small very hard or fibrous tumors.

Competitive Advantages

Unique, combined diagnostic and therapy methods.

Fourier/AS: The company's Fourier/AS method for biopsy sampling delivers high yield biopsies from fewer insertions. This facilitates a secure diagnosis and minimizes the dissemination of tumor cells into the body. Force-proportional oscillatory micro-movements are used to slowly and evenly insert the biopsy needle. This enables gentle insertion, decreasing biopsy bleeding and seeding and unnecessary damage to tissue at the rear of the tumor.

PRFA: Allows high-precision penetration of the treatment electrode into the tumor. As a day surgery involving only local anesthesia and very short treatment time it minimizes patient inconvenience and health care costs.

The Market

The cancer diagnostic and therapeutic market is expected to experience a steady growth due to demographic changes. The global biopsy market is estimated at USD 1bn. More than 10,000 biopsies per million of population are carried out for suspected cancer in the developed world. The largest indications for biopsies are suspected breast and prostate cancer.

The market for minimally-invasive treatment of cancer and more benign changes in the breast is established and growing, and is expected to reach USD 200m in the USA soon¹.

.

Status

Fourier/AS

• Local occurrence of living tumor cells in breast biopsies, and that these can be eliminated with Fourier/AS, has been established and the data published, generating a lot of attention²
• New proprietary equipment has been developed for Core Needle Biopsy
• Core Needle Biopsy is going through market-acceptance testing